Trial Condition(s):

Multiple Sclerosis

Evaluation of potential predictors of adherence by investigating a representative cohort of Multiple Sclerosis (MS) patients in Germany treated with Betaferon (BETAPREDICT)

Bayer Identifier:

18016

ClinicalTrials.gov Identifier:

NCT02486640

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This study aims to evaluate potential predictors of adherence by investigating a representative cohort of MS patients in Germany treated with Betaferon

Inclusion Criteria
-Patients aged ≥ 18 years with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome
-Patients on treatment with Betaferon or the decision to treat patients with Betaferon has been made by the attending physician
-Patients using or willing to use the BETACONNECT autoinjector for Betaferon application
-Written informed consent
Exclusion Criteria
-Patients receiving any other disease modifying drug
-Contraindications of Betaferon described in the Summary of Product Characteristics
-Patients participating in any other clinical or non-interventional study, evaluating MS therapy

Trial Summary

Enrollment Goal
162
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Betaseron (Interferon beta-1b, BAY86-5046)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many locations, Germany

Status
Active, not recruiting
 

Trial Design